Today: 20 May 2026
Browse Category

CSE:NOVOB.CO 10 January 2026 - 9 February 2026

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.
9 February 2026
····
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk B shares rose 5.29% to 295.50 Danish crowns Friday after Hims & Hers said it would stop selling a $49 compounded version of Novo’s Wegovy pill. The rebound followed a steep two-day drop and came as the FDA pledged action against mass-marketed copycats. The stock remains down about 20% over five sessions. Investors remain uncertain about Novo’s patent protections and future pricing power.
8 February 2026
···
Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk shares rose 3% to 381.45 crowns in Copenhagen after Amazon Pharmacy began selling its new Wegovy weight-loss pill in the U.S. The pill, approved by the FDA in December, puts Novo ahead of Eli Lilly in the obesity pill market. About 8.95 million shares traded Friday, with prices ranging from 369.0 to 389.8 crowns. Novo will report full-year results on Feb. 4.
10 January 2026
··

Stock Market Today

  • Euronext Reports Eighth Consecutive Quarter of Double-Digit Growth in Q1 2026
    May 20, 2026, 4:43 AM EDT. Euronext posted strong Q1 2026 results, marking its eighth straight quarter of double-digit growth. The exchange operator reported record performance in non-volume related revenues, underscoring its diversified income streams beyond trading volumes. This robust start to the year highlights Euronext's expanding role in European financial markets, supported by strategic investments and product offerings. The results reflect continued market confidence amid evolving economic conditions.

Latest articles

Chewy Shares Slide on CEO Talk of “Stretched Consumer”

Chewy Shares Slide on CEO Talk of “Stretched Consumer”

20 May 2026
Chewy Inc. shares dropped 9.1% to $19.66 Tuesday after CEO Sumit Singh warned U.S. consumers are more financially strained than earlier this year. The decline put Chewy near its 52-week low ahead of its June 10 earnings report. Singh made the comments at a J.P. Morgan conference, citing multiple data points on weaker consumer demand. Petco fell 2.9%, while BARK rose 7.5% and Amazon slipped 2.1%.
Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

20 May 2026
Meiwu Technology shares jumped 97% to $4.75 Tuesday and rose another 12% premarket after the company raised $15.65 million in a private share sale to fund an AI skincare platform. The rally follows a 1-for-100 reverse share split in April and earlier $14 million direct offering. Meiwu warned its new platform is early-stage and faces regulatory risks.
Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

20 May 2026
Astera Labs shares rose 13.3% to $244.26 on Tuesday after management outlined a faster ramp for its Scorpio X fabric switches and optical networking tied to Nvidia’s NVLink Fusion. The move followed presentations at J.P. Morgan’s tech conference and comes ahead of Nvidia’s earnings Wednesday. Astera’s first-quarter revenue jumped 93% to $308.4 million, with second-quarter guidance above analyst forecasts.
Go toTop